"A leading nephrology journal has rejected a guest editorial questioning the efficacy of epoetin in end stage renal disease, despite favourable peer reviews, apparently because it feared losing advertising."
Journal rejects article after objections from marketing department
Owen Dyer
BMJ 2004;328:244

